CEA-----CAS
CREST: Study Overview
Carotid Revascularization Endarterectomy vs. Stenting Trial
Design Stent/EPD Prospective, Multicenter, Randomized 1:1 CEA to CAS RX Acculink® / RX Accunet®
Accunet 30days I/stroke/D8.3%,1yrsstroke/D9.6% FilterWire 30days I/stroke/D5.8%,1yrs stroke/D9.1% FilterWire 30days I/stroke/D3.8%,1yrs stroke/D4.5% Accunet 30days I/stroke/D5.7%, Guardwire plus 30days I/stroke/D2.1%, spider OTW 30days I/stroke/D6.2%, spiderRX 30days I/stroke/D5.6%, RX Accunet 30days I/stroke/D4.4%, Guardwire 30days I/stroke/D5.1%, Guardwire 30days I/stroke/D5.3%, MO.MA 30days I/stroke/D5.7%, MO.MA 30days I/stroke/D4.6%, Emboshield 30days I/stroke/D8.5%,
Apr 2008
2008
2009
2010
Dec 2000
Oct 2009 Jul 2008 Feb 2010
Source: William W Gray. Reading the Tea Leaves: Possible Outcomes from the CREST Trial and Effects on the Field. TCT, San Francisco, CA; 2009. Lal BK, Brott TG. The Carotid Revascularization Endarterectomy vs. Stenting Trial completes randomization: Lessons learned and anticipated results. J Vasc Surg 2009; 50:1224-1231.